Table 1.

Association Between Sustained Virological Response at 12 Weeks and Progression of Liver Disease as Measured by the Aspartate Aminotransferase:Platelet Ratio Index, Canadian HIV–Hepatitis C Co-infection Cohort Study, 2004–2016^a

Variable	Exposure Model Specification
	Linear		Splines		FP		CBPS
	$\stackrel{\mathbf{ˆ}}{\mathbf{\beta }}$	95% CI	$\stackrel{\mathbf{ˆ}}{\mathbf{\beta }}$	95% CI	$\stackrel{\mathbf{ˆ}}{\mathbf{\beta }}$	95% CI	$\stackrel{\mathbf{ˆ}}{\mathbf{\beta }}$	95% CI
SVR12b status	−0.11	−0.20, −0.03	−0.11	−0.20, −0.03	−0.11	−0.19, −0.02	−0.13	−0.21, −0.04
Female sex	−0.09	−0.21, 0.05	−0.09	−0.22, 0.04	−0.09	−0.22, 0.04	−0.08	−0.21, 0.05
BMIc (per 10 units)	−0.01	−0.10, 0.07	−0.01	−0.11, 0.08	−0.01	−0.11, 0.08	−0.01	−0.11, 0.08
Age (per 10 years)	−0.01	−0.07, 0.04	−0.02	−0.08, 0.04	−0.02	−0.08, 0.04	−0.02	−0.08, 0.05
Injection drug use in preceding 6 months	−0.05	−0.17, 0.07	−0.05	−0.18, 0.07	−0.05	−0.17, 0.08	−0.04	−0.17, 0.09
Duration of HCV infection (per 10 years)	0.04	0.00, 0.08	0.04	−0.01, 0.08	0.04	−0.01, 0.08	0.04	−0.01, 0.08
HCV genotype of 2, 3, or 4 vs. HCV genotype 1	0.13	0.03, 0.25	0.14	0.03, 0.26	0.14	0.03, 0.26	0.13	0.03, 0.25

Abbreviations: BMI, body mass index; CBPS, covariate-balancing propensity score; CI, confidence interval; FP, fractional polynomial; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR, sustained virological response.

^a 95% CIs were computed by means of the nonparametric bootstrap percentiles approach.

^b SVR 12 weeks after discontinuation of HCV therapy.

^c BMI was calculated as weight (kg)/height (m)².